Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA
Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland, USA.
Clin Microbiol Rev. 2019 Jul 31;32(4). doi: 10.1128/CMR.00019-19. Print 2019 Sep 18.
Protozoan parasites are the causative agents of malaria, a deadly disease that continues to afflict hundreds of millions of people every year. Infections with malaria parasites can be asymptomatic, with mild or severe symptoms, or fatal, depending on many factors such as parasite virulence and host immune status. Malaria can be treated with various drugs, with artemisinin-based combination therapies (ACTs) being the first-line choice. Recent advances in genetics and genomics of malaria parasites have contributed greatly to our understanding of parasite population dynamics, transmission, drug responses, and pathogenesis. However, knowledge gaps in parasite biology and host-parasite interactions still remain. Parasites resistant to multiple antimalarial drugs have emerged, while advanced clinical trials have shown partial efficacy for one available vaccine. Here we discuss genetic and genomic studies of biology, host-parasite interactions, population structures, mosquito infectivity, antigenic variation, and targets for treatment and immunization. Knowledge from these studies will advance our understanding of malaria pathogenesis, epidemiology, and evolution and will support work to discover and develop new medicines and vaccines.
原生动物寄生虫是疟疾的病原体,疟疾是一种致命疾病,每年仍有数亿人感染。疟原虫感染可能无症状,也可能出现轻微或严重症状,甚至致命,具体取决于寄生虫毒力和宿主免疫状态等多种因素。疟疾可以用各种药物治疗,青蒿素为基础的联合疗法(ACT)是首选。寄生虫遗传学和基因组学的最新进展极大地促进了我们对寄生虫种群动态、传播、药物反应和发病机制的理解。然而,寄生虫生物学和宿主-寄生虫相互作用方面的知识空白仍然存在。对多种抗疟药物具有耐药性的寄生虫已经出现,而先进的临床试验表明,现有疫苗的部分疗效。在这里,我们讨论了生物学、宿主-寄生虫相互作用、种群结构、蚊子感染性、抗原变异以及治疗和免疫接种靶点的遗传和基因组研究。这些研究的知识将促进我们对疟疾发病机制、流行病学和进化的理解,并支持发现和开发新药物和疫苗的工作。